Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB8600 First-in-Human Study
NCT04444466Phase 1Terminated
- Sponsor
- UCB
- Start
- Jun 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic spontaneous urticaria (CSU) comparing UCB8600 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Started Jun 2020; status: terminated.
02
Drugs
UCB8600
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04444466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444466.